Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions
Author:
Mathew DivijORCID, Giles Josephine R., Baxter Amy E.ORCID, Greenplate Allison R.ORCID, Wu Jennifer E., Alanio CécileORCID, Oldridge Derek A.ORCID, Kuri-Cervantes LeticiaORCID, Pampena M. Betina, D’Andrea Kurt, Manne Sasikanth, Chen Zeyu, Huang Yinghui Jane, Reilly John P., Weisman Ariel R, Ittner Caroline A.G., Kuthuru Oliva, Dougherty Jeanette, Nzingha Kito, Han Nicholas, Kim Justin, Pattekar Ajinkya, Goodwin Eileen C., Anderson Elizabeth M., Weirick Madison E., Gouma SigridORCID, Arevalo Claudia P., Bolton Marcus J., Chen Fang, Lacey Simon F., Hensley Scott E.ORCID, Apostolidis SokratisORCID, Huang Alexander C., Vella Laura A., Betts Michael R.ORCID, Meyer Nuala J.ORCID, Wherry E. JohnORCID,
Abstract
AbstractCOVID-19 has become a global pandemic. Immune dysregulation has been implicated, but immune responses remain poorly understood. We analyzed 71 COVID-19 patients compared to recovered and healthy subjects using high dimensional cytometry. Integrated analysis of ∼200 immune and >30 clinical features revealed activation of T cell and B cell subsets, but only in some patients. A subgroup of patients had T cell activation characteristic of acute viral infection and plasmablast responses could reach >30% of circulating B cells. However, another subgroup had lymphocyte activation comparable to uninfected subjects. Stable versus dynamic immunological signatures were identified and linked to trajectories of disease severity change. These analyses identified three “immunotypes” associated with poor clinical trajectories versus improving health. These immunotypes may have implications for therapeutics and vaccines.
Publisher
Cold Spring Harbor Laboratory
Reference57 articles.
1. E. Iype , S. Gulati , Understanding the asymmetric spread and case fatality rate (CFR) for COVID-19 among countries. medRxiv (2020) (available at https://www.medrxiv.org/content/10.1101/2020.04.21.20073791v1.abstract). 2. Cytokine release syndrome in severe COVID-19 3. COVID-19 infection: the perspectives on immune responses;Cell Death Differ,2020 4. N. Vabret , G. J. Britton , C. Gruber , S. Hegde , J. Kim , M. Kuksin , R. Levantovsky , L. Malle , A. Moreira , M. D. Park , L. Pia , E. Risson , M. Saffern , B. Salomé , M. E. Selvan , M. P. Spindler , J. Tan , V. van der Heide , J. K. Gregory , K. Alexandropoulos , N. Bhardwaj , B. D. Brown , B. Greenbaum , Z. H. Gümüs , D. Homann , A. Horowitz , A. O. Kamphorst , M. A. Curotto de Lafaille , S. Mehandru , M. Merad , R. M. Samstein , Immunology of COVID-19: current state of the science. Immunity (2020), doi :10.1016/j.immuni.2020.05.002. 5. D. Weiskopf , K. S. Schmitz , M. P. Raadsen , A. Grifoni , N. M. A. Okba , H. Endeman , J. P. C. van den Akker , R. Molenkamp , M. P. G. Koopmans , E. C. M. van Gorp , Others, Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome. medRxiv (2020) (available at https://www.medrxiv.org/content/10.1101/2020.04.11.20062349v1.abstract).
Cited by
260 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|